检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:岑晶[1] 顾锋[1] 金自孟[1] 伍学焱[1] 朱惠娟[1] 李乃适[1] 茅江峰[1] 段炼[1] 岳欣[1]
机构地区:[1]中国医学科学院北京协和医学院北京协和医院内分泌科卫生部内分泌重点实验室,北京100730
出 处:《中国实用内科杂志》2012年第7期543-546,共4页Chinese Journal of Practical Internal Medicine
摘 要:目的评价初始长效生长抑素类似物联合手术治疗肢端肥大症的临床疗效。方法回顾性分析2005—2008年在北京协和医院内分泌科收治并定期随访的初始长效生长抑素类似物(SSA)治疗联合经蝶手术切除垂体腺瘤并经病理证实的23例肢端肥大症患者病历资料。结果肢端肥大症患者长效SSA治疗(≥3个月)后生长激素(GH)谷值明显降低(P<0.01),肿瘤体积缩小(P=0.012)。术前生化控制组(GH<0.047 nmol/L)较未控制组(GH≥0.047 nmol/L)肿瘤体积小(P=0.015),术后初次(P=0.002)及末次随访(P=0.018)GH谷值低。结论肢端肥大症患者术前应用长效SSA治疗可降低术前GH水平、缩小肿瘤体积,是提高手术疗效的原因之一;术前口服葡萄糖耐量试验GH谷值可用于评价肢端肥大症患者的手术预后。Objective To study the efficacy of somatostatin analogues (SSA) with surgery combined in patients with acro megaly. Methods We performed a retrospective study on the clinical profiles in 23 patients withpathologically-confirmed acromegaly who were treated with presurgical SSA in combination with transsphenoidal tumr resection and underwent longterm followed-ups in the department of endocrinology, Peking Union Hospital between January 1 st, 2005 and December 31 st ,2008. Results Treatment with SSA in patients with acromegaly for 〉 3 months led to marked reduction in the nadir of growth hormone (GH) (P 〈 0. 01 ) and shrinking of tumor volume (P = 0. 012 ). Biochemically controlled group (GH 〈 0. 047 nmol/L) yielded considerbly smaller tumor size than uncontrolled group (GH≥0. 047 nmol/L) (P = 0. 015 ) prior to the surgery. In addition, both initial and final GH nadirs were reduced postoperatively (P = 0. 002 and 0. 018, respectively). Conclusion SSAs in patients with acromegaly may be associated with improved efficacy of surgery as a result of reduced GH level and shrinked tumor volume prior to surgery. Preoperative detection of GH nadir via OGTI may be applied to assess the prognosis of patients with acromegaly.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.36